GDUFA Launch Pains: Facility List Fluctuations, Back-Due Backlog Fees
Executive Summary
FDA still has backlog fees in arrears more than two months past the payment deadline, but cannot forcibly withdraw the applications; facility listings also change consistently because industry can update them as needed.
You may also be interested in...
GDUFA: Fee Avoidance Affects Rates Again
Industry avoided application supplement fees by using CBE submissions instead, forcing FDA to change its estimates and sending generic drug user fees higher.
GDUFA: FDA Sees High Fee Collection Rate After First Six Months
About 24% of facility fees and 20% of all fees are outstanding, but industry officials also want to measure success through FDA hiring and communication.
Growing Pains for Generic Drugs: OGD Gains Respect, But Loses Geba
FDA’s Office of Generic Drugs was at the start of a turnaround: $299 million in new user fees to clear a big ANDA backlog and fund overseas inspections, an elevated status within the Center for Drugs and a brand-new director to steer the ship. But there have been some bumps in GDUFA implementation, and OGD’s new director, Gregory Geba, has abruptly left the agency. What next for FDA’s generic drug oversight?